

# CURRICULUM VITAE

## Ja Min BYUN, MD, PHD

Country Republic of Korea  
Address Division of Hematology and Medical Oncology  
Department of Internal Medicine,  
Seoul National University Hospital  
101 Daehak-ro, Jongno-gu  
Seoul, KOREA, REPUBLIC OF (03080)  
E-mail [jaminbyun@naver.com](mailto:jaminbyun@naver.com)  
Secondary e-mail [jaminbyun@snu.ac.kr](mailto:jaminbyun@snu.ac.kr)  
Phone +82-2-2072-1477  
Fax +82-2-762-9662  
ORCID [orcid.org/0000-0003-1780-5553](https://orcid.org/0000-0003-1780-5553)

### Education (university and/or medical)

2004-2010 Kyung Hee University College of Medicine, Seoul, Korea  
2013-2015 Master's degree, Kyung Hee University, Seoul, Korea  
2015-2019 Doctor of Philosophy, Seoul National University, Seoul, Korea

### Postgraduate training

2010.3 – 2011.2 Internship in Kyung Hee University Hospital, Seoul, Korea  
2011.3 – 2015.2 Residency in the department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea  
2015.3 – 2017.2 Clinical fellowship in the division of Hematology and Oncology, department of Internal Medicine, Seoul National University Hospital, Seoul, Korea  
2016.7 – 2016.8 Visiting scientist at Ontario Institute for Cancer Research (OICR), Toronto, Ontario, Canada  
2017.3 – 2019.5 Clinical assistant professor in the division of Hematology and

Oncology, department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea

### **Grants**

2015 Korea Health Industry Development Institute HC15C3397  
2017 NRF-2017R1D1A1B03035151  
2019 NRF-2020R1F1A10761

### **Credentials**

2010 Medical license, Korea (103039)  
2013 ECFMG, USA (0-793-788-1)  
2015 Internal medicine specialist, Korea (15728)  
2017 Hematology/Medical Oncology subspecialist, Korea (6-17-556)

### **Awards**

2014 Asian Organization for Crohn's and Colitis (AOCC) 2014 Distinguished Investigator Award  
2016 Korean Cancer Research Foundation (KCRF)/Korean Association for Clinical Oncology (KACO) scholarship  
2017 Korean Cancer Research Foundation (KCRF) Distinguished Research Award  
2017 Best Oral Presentation Award, The 58<sup>th</sup> Korean Society of Hematology Annual Meeting  
2019 Best Oral Presentation Award, The 60<sup>th</sup> Korean Society of Hematology Annual Meeting  
2021 Best Poster Presentation Award, Korean Society of Hematology International Conference & 62<sup>nd</sup> Annual Meeting

### **GCP Training**

Jul. 2020 ~ Jun. 2021 GCP training

### **Current position**

Jun. 2019 – Present      Clinical assistant professor in the division of Hematology and Oncology, department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

### **Trials (only as principal investigator)**

1. A multicenter, open-label, phase 4 clinical study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment
2. 2215-CL-0201, A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
3. ACE-536-MDS-002, A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects who require Red Blood Cell Transfusions.
4. ACE-536-MF-002, A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

### **DSMB / DMC / IDMC experience**

None

### **Publications (only as first or corresponding author, research paper only, recent 4 years)**

1. Han H, **Byun JM**, Shin DY et al. Leukemic stem cell phenotype is associated with mutational profile in acute myeloid leukemia. Korean J Intern Med. 2021 Mar;36(2):401-412.

2. Oh MJ, Shin DY, Koh Y, Hong J, Kim I, Yoon SS, Byun JM. A Pilot Study of allogeneic hematopoietic stem cell transplantation for intermediate-risk acute leukemia patients. *In Vivo*. 2021 Jan-Feb;35(1):617-622.
3. **Byun JM**, Yoon SS, Koh Y et al. Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd). *Ther Adv Hematol*. 2020 May;12:11: 2040620720921046.
4. **Byun JM**, Lee JO, Suh KJ et al. The role of anthracyclines in acute myeloid leukemia consolidation. *Anticancer Res*. 2020 Jan;40(1):357-366.
5. **Byun JM**, Kim S, Yoon SS et al. Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk. *Anticancer Res*. 2020 May;40(5):2917-2924.
6. **Byun JM**, Hong J, Oh D et al. Optimizing preparative regimen for umbilical cord blood transplantation in adult acute leukemia patients: acute lymphoblastic leukemia requires myeloablative conditioning but not acute myeloid leukemia. *J Clin Med*. 2020 Jul 21;9(7):2310
7. **Byun JM**, Kwon YN, Koh Y et al. Distinctive patterns of peripheral neuropathy across the spectrum of plasma cell disorders. *Sci Rep*. 2019 Nov 14;9(1):16769.
8. **Byun JM**, Song S, Koh Y et al. The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms. *Anticancer Res*. 2019 Nov;39(11):6273-6282.
9. **Byun JM**, Hong J, Yoon SS et al. Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy. *Thromb Res*. 2019 Nov;183:131-135.
10. Park H, **Byun JM**, Koh Y et al. Comparison of Different Conditioning Regimens in Allogeneic Hematopoietic Stem-Cell Transplantation Shows Superiority of Total Body Irradiation-Based Regimen for Younger Patients With Acute Leukemia: A Nationwide Study. *Clin Lymphoma Myeloma Leuk*. 2019 Nov;19(11):e605-e615
11. **Byun JM**, Yoon SS, Koh Y et al. Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience. *Anticancer Res*. 2019 Sep;39(9):5165-5170.

12. **Byun JM**, Kim D, Shin DY et al. Combination of Genetic Aberration With International Staging System Classification for Stratification of Asian Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. *In Vivo*. 2019 Mar-Apr;33(2):611-619.
13. **Byun JM**, Shin DY, Hong J et al. Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients. *Cancer Med*. 2018 Mar;7(3):831-841.
14. **Byun JM**, Lee J, Shin SJ et al. Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma. *Blood Res*. 2018 Jun;53(2):105-109.
15. Kim YA, **Byun JM**, Park K et al. Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma. *Blood Adv*. 2017 Oct 27;1(24):2138-2146.
16. **Byun JM**, Kim KH, Kim M et al. Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience. *Leuk Lymphoma*. 2017 Nov;58(11):2624-2632.
17. **Byun JM**, Koh Y, Shin DY et al. BCR-ABL translocation as a favorable prognostic factor in elderly acute lymphoblastic leukemia patients in potent tyrosine kinase era. *Haematologica*. 2017 May;102(5):e187-e190.
18. **Byun JM**, Kim YJ, Youk T et al. Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013. *Ann Hematol*. 2017 Mar;96(3):373-381.
19. **Byun JM**, Kim HL, Shin DY et al. The Impact of Methylenetetrahydrofolate Reductase C677T Polymorphism on Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation with Methotrexate Prophylaxis. *PLoS One*. 2016 Oct 26;11(10):e0163998.
20. **Byun JM**, Shin DY, Koh Y et al. Survival disparities in patients with relapsed core-binding factor acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. *Int J Clin Exp Med* 2016;9(12):23285-23593.
21. **Byun JM**, Lee JO, Kang B et al. Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian population. *Clin Lymphoma Myeloma Leuk*. 2016 Sep;16(9):503-510.

22. **Byun JM**, Kim YJ, Yoon HJ et al. Cytogenetic profiles of 2806 patients with acute myeloid leukemia – a retrospective multicenter nationwide study. *Ann Hematol.* 2016 Aug;96(8):1223-23.

A handwritten signature in black ink, appearing to read "Jamis Byun". The signature is fluid and cursive, with a prominent loop at the end.